tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Recursion Pharmaceuticals price target lowered to $5 from $8 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5 from $8 and keeps an Equal Weight rating on the shares. The firm revised its model following the company’s recent pipeline prioritizations, cost reductions, 20% workforce reduction and updated cash burn guidance.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1